Related Experiment Videos
Potent activation of mouse macrophages by recombinant interferon-gamma
Abstract:
The ability of recombinant interferon-gamma (IFN-gamma) to activate mouse macrophages was investigated. The use of recombinant IFN-gamma has the advantage of being devoid of contaminating lymphokines. Two preparations of IFN-gamma were utilized, one which was not glycosylated and which was highly purified from Escherichia coli another which was glycosylated and which was from transfected COS-7 monkey cells. Both preparations of recombinant IFN-gamma activated murine macrophages to kill lymphoma and melanoma tumor targets, suggesting that glycosylation of the protein or the presence of other mammalian proteins is not essential for activation. Significant levels of cytolytic activity were induced from IFN-gamma (1 to 10 units/ml). This activity was undiminished by treatment of the IFN-gamma preparations with polymixin B at doses which neutralized endotoxin (50 micrograms/ml). Similarly, IFN-gamma, at low concentrations, induced an inhibition of migration by macrophages. Based on antiviral activity, IFN-gamma was shown to be 100 to 1000 times more potent than was IFN-beta as a macrophage-activating agent. Taken together, these results demonstrate that murine IFN-gamma is a macrophage-activating factor which is effective at physiological concentrations. Of particular interest is the observation that the nonglycosylated E. coli-derived IFN-gamma is active and therefore may be of value for therapeutic studies, since it can be easily produced in large amounts.
Insights
Recombinant interferon-gamma (IFN-gamma) effectively activates mouse macrophages to combat tumor cells. Both glycosylated and non-glycosylated forms are potent macrophage-activating factors, even at low concentrations, showing therapeutic potential.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Recombinant interferon-gamma (IFN-gamma) is a key cytokine in immune responses.
- Investigating its role in macrophage activation is crucial for understanding immune mechanisms.
Purpose of the Study:
- To determine the ability of recombinant IFN-gamma to activate mouse macrophages.
- To assess the impact of glycosylation on IFN-gamma's macrophage-activating properties.
Main Methods:
- Utilized two preparations of recombinant IFN-gamma: non-glycosylated (E. coli-derived) and glycosylated (COS-7 cell-derived).
- Assessed macrophage activation by measuring cytolytic activity against tumor targets and macrophage migration inhibition.
- Tested the effect of polymixin B to rule out endotoxin contamination.
Main Results:
- Both glycosylated and non-glycosylated recombinant IFN-gamma activated murine macrophages to kill lymphoma and melanoma tumor cells.
- Significant cytolytic activity was observed at 1-10 units/ml IFN-gamma, unaffected by polymixin B.
- IFN-gamma induced macrophage migration inhibition and was 100-1000 times more potent than IFN-beta as a macrophage activator.
Conclusions:
- Recombinant IFN-gamma is a potent macrophage-activating factor effective at physiological concentrations.
- Glycosylation and mammalian protein presence are not essential for IFN-gamma's macrophage-activating function.
- Non-glycosylated, E. coli-derived IFN-gamma shows therapeutic potential due to its activity and ease of production.